Clenbuterol (hydrochloride) (Synonyms: NAB 365,Ventipulmin) |
| Catalog No.GC12778 |
sympathomimetic β2-adrenoceptor agonist used as a bronchodilator in the treatment of pulmonary diseases
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 21898-19-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Clenbuterol is a sympathomimetic β2-adrenoceptor agonist.
β2-adrenoceptor agonists, mainly long-acting β2-adrenoceptor agonists, are an important pharmacological approach to induce bronchodilation in patients with chronic obstructive pulmonary disease.
In vitro: A hormone dependent human breast cancer cell line was treated with different concentrations of clenbuterol. It was found that clenbuterol could stimulate cell proliferation at low concentrations, but the effect was less marked and significant compared with oestradiol. Probably clenbuterol elicited cell proliferation via a different mechanism, because it did not affect the cellular oestrogen receptor concentration [1].
In vivo: Clenbuterol was administered to Fischer-344 rats, at a dose of 1.5 mg/kg/24 h for 3 weeks. The weights of five hindlimb muscles and carcass protein and fat content were determined. Results showed that clenbuterol treatment could increase the weight of skeletal muscles of all animals. Similarly, clenbuterol increased carcass protein conten, leading to the reduced carcass fat content [2].
Clinical trial: Clenbuterol was compared with terbutaline during a 5-week single-blind crossover study in patients with chronic airways obstruction. Both clenbuterol and terbutaline could significantly improve baseline FEV1 and the bronchodilator effects were similar, suggesting that clenbuterol was a good alternative drug for treatment of chronic airways obstruction [3].
References:
[1] Re G, Badino P, Girardi C, Di Carlo F. Effects of a beta 2-agonist (clenbuterol) on cultured human (CG-5) breast cancer cells. Pharmacol Res. 1992 Dec;26(4):377-84.
[2] Carter WJ, Dang AQ, Faas FH, Lynch ME. Effects of clenbuterol on skeletal muscle mass, body composition, and recovery from surgical stress in senescent rats. Metabolism. 1991 Aug;40(8):855-60.
[3] Brusasco V, Crimi E, Mangini S, Vibelli C. A clinical trial of oral clenbuterol (NAB 365) in chronic airways obstruction. Curr Med Res Opin. 1980;6(7):449-55.
Average Rating: 5 (Based on Reviews and 7 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *